ReviewFrontiers in neurology2025
Systematic evaluation of neuro-ophthalmic outcomes of the ophthalmic artery covered by flow-diverter.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mid- and Long-Term Outcomes Following Flow Diversion for Carotid-Ophthalmic Aneurysms: a Single-Centre Experience.Clinical neuroradiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carotid-ophthalmic aneurysms (COA) are complex and severe intracranial arterial lesions, and their treatment and management have always been a focus of clinical research. In recent years, the introduction of flow diverters (FD) has provided a revolutionary method for the treatment of intracranial aneurysms (IA). Although FD has achieved significant success in reducing the risk of COA rupture, the complex anatomical structure and critical function of the ophthalmic artery (OphA) mean that covering the OphA with FD may lead to adverse ophthalmic outcomes. This review aims to systematically examine the ocular complications and their mechanisms when FD covers the OphA in the treatment of COA, emphasizing the potential risks that clinicians should be aware of when applying FD treatment, to reduce complications and improve the overall prognosis of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.